Effect of dutasteride for relieving benign prostatic obstruction

Effect of dutasteride for relieving benign prostatic obstruction - AVO PFS Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004454

Enrollment

Registered

2010-10-26

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostatic Hyperplasia

Interventions

Dutasteride 0.5mg/day for 24 months

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Subjects who meet all the following criteria will be enrolled. 1 Age >= 50 yrs 2 IPSS >= 8 3 IPSS QOL >= 3 4 Prostate volume >= 25mL measured by abdominal ultarsonograpy 5 Qmax < 15mL/sec

Exclusion criteria

Exclusion criteria: Subjects who apply to any of the following criteria will not be enrolled. 1 Use of any alpha-blocker within 4 weeks 2 Previous use of 5ARIs or antiandrogens 3 History of prostate cancer 4 History of acute urinary retention (AUR) within 3 months 5 Previous prostatic surgery

Design outcomes

Primary

Measure	Time frame
Change from baseline in PFS parameter	—

Secondary

Measure	Time frame
IPSS OABSS Urinary flow Post voided residual volume Safety	—

Countries

Japan

Contacts

Public ContactYoshihisa Matsukawa

Nagoya University Graduate School of Medicine Department of Urology

yoshi44@med.nagoya-u.ac.jp+81-52-744-2985

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026